|
|
Blood, 1 September 2005, Vol. 106, No. 5, pp. 1839-1842.
Prepublished online as a Blood First Edition Paper on May 5, 2005; DOI 10.1182/blood-2005-01-0427.
 Previous Article | Next Article 
Submitted January 31, 2005
Accepted April 29, 2005
The fully human anti-CD30 antibody 5F11 activates NF-kB and sensitizes lymphoma cells to bortezomib-induced apoptosis
Boris Boll, Hinrich Hansen, Friederike Heuck, Katrin Reiners, Peter Borchmann, Achim Rothe, Andreas Engert*, and Elke Pogge von Strandmann
Laboratory for Immunotherapy, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany
* Corresponding author; email: elke.pogge{at}medizin.uni-kolen.de.
5F11, a fully human monoclonal antibody directed against CD30 effectively induces killing of CD30-expressing lymphoma cell lines in vitro and in animal models. A recently conducted phase I/II study shows that 5F11 is well tolerated in heavily pre-treated patients with relapsed and refractory CD30-positive lymphoma and has some clinical activity.
In the present study we demonstrate that 5F11 activates NF-kB and the anti-apoptotic protein c-flip in HD (Hodgkins lymphoma)-derived cell lines, which might cause apoptosis resistance thus limiting its clinical use. To overcome this resistance we combined 5F11 with the proteasome inhibitor bortezomib which has been shown to suppress NF-kB activity. This combination revealed a synergistic cytotoxic effect in vitro and in a human HD xenograft model provided that 5F11 precedes bortezomib treatment. We conclude that initial 5F11-mediated NF-kB signaling sensitizes the tumor cells to bortezomib-induced cell death. These data suggest a therapeutic value of this combination for HD patients.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. H. Mendler, J. Kelly, S. Voci, D. Marquis, L. Rich, R. M. Rossi, S. H. Bernstein, C. T. Jordan, J. Liesveld, R. I. Fisher, et al.
Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma
Ann. Onc.,
May 25, 2008;
(2008)
mdn365v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Hirsch, M. Hummel, S. Bentink, F. Fouladi, R. Spang, R. Zollinger, H. Stein, and H. Durkop
CD30-Induced Signaling Is Absent in Hodgkin's Cells but Present in Anaplastic Large Cell Lymphoma Cells
Am. J. Pathol.,
February 1, 2008;
172(2):
510 - 520.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Ansell, S. M. Horwitz, A. Engert, K. D. Khan, T. Lin, R. Strair, T. Keler, R. Graziano, D. Blanset, M. Yellin, et al.
Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma
J. Clin. Oncol.,
July 1, 2007;
25(19):
2764 - 2769.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. von Tresckow, E. P. von Strandmann, S. Sasse, S. Tawadros, A. Engert, and H. P. Hansen
Simvastatin-dependent apoptosis in Hodgkin's lymphoma cells and growth impairment of human Hodgkin's tumors in vivo
Haematologica,
May 1, 2007;
92(5):
682 - 685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Trelle, O. Sezer, R. Naumann, M. Rummel, U. Keller, A. Engert, and P. Borchmann
Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018)
Haematologica,
April 1, 2007;
92(4):
568 - 569.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-P. Armand, A. K. Burnett, J. Drach, J.-L. Harousseau, B. Lowenberg, and J. San Miguel
The Emerging Role of Targeted Therapy for Hematologic Malignancies: Update on Bortezomib and Tipifarnib
Oncologist,
March 1, 2007;
12(3):
281 - 290.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
